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Rheumatoid arthritis (RA) is an inflammatory
disorder that affects 1% of the adult population
worldwide. The hallmark of RA is leukocytic in-
filtration of the synovium.1 This inflammatory
process stimulates the proliferation of apoptosis-
resistant fibroblast-like synoviocytes (FLS), which
leads to pannus formation and joint destruc-
tion.2,3 Intra-articular expression of proinflam-
matory cytokines, in particular tumor necrosis
factor (TNF)-α and interleukin (IL)-1β, play key
roles in the pathogenesis of RA.4 Inflammatory
cytokines such as IL-1β, IL-6, and TNF-α also
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Background/Purpose: Antibodies against type II collagen (anti-CII) are arthritogenic and central to the
initiation of the disease. An animal model of collagen type II-specific monoclonal antibody-induced
arthritis (CAIA) has been used for the evaluation of various therapeutic effects in rheumatoid arthritis
(RA). We aimed to measure the expression of matrix metalloproteinase (MMP)-9 (gelatinase B), tumor
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the acute and chronic stages of the CAIA model
for application as a therapeutic marker.
Methods: A commercially available antibody cocktail containing four monoclonal anti-type II collagen anti-
bodies were injected into 6–8-week-old male BALB/c mice (n = 20) and 50 µL lipopolysaccharide was injected
3 days later. The clinical manifestations of RA were recorded and scored at 10 days (acute stage) and 21 days
(chronic stage). Then the mice were sacrificed for histologic analysis of the inflamed footpad and gene ex-
pression of IL-1β, TNF-α and MMP-9 by ELISA and quantitative polymerase chain reaction amplification.
Results: Marked inflammation was found in the limb joints of mice at 10 days. Both IL-1β and MMP-9 
expression played a central role in the inflammatory reaction in the acute stage. The expression level of
MMP-9 mRNA remained high in the chronic stage of CAIA, but that of IL-1β mRNA was unexpectedly
negligible; the serum level of TNF-α in CAIA was undetectable in the acute stage. The expression level of
TNF-α mRNA was also lower than IL-1β and MMP-9 in the acute inflammatory stage.
Conclusion: The CAIA model is a fast and highly replicable model of RA. MMP-9 and IL-1β were highly
expressed in the acute stage of CAIA. It is suggested the MMP-9 mRNA level is a suitable marker for both
acute and chronic stage, whereas IL-1β is a marker only for the acute stage of the CAIA murine model. 
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contribute to the development of arthritis in some
arthritis models.5–8 IL-1β has various physiologic
functions such as the induction of inflammation,
modification of the immune response, and acti-
vation of osteoclasts.9–12 IL-6 and TNF-α are also
involved in inflammation and in the differentia-
tion and proliferation of T and B lymphocytes
and bone absorption.12–16
Massive secretion of members of the matrix
metalloproteinase (MMP) family is conspicuous
in several inflammatory disorders including ar-
thritis. MMP-9 is highly expressed in monocytes
(osteoclast precursors) and in multinucleated 
osteoclasts that resorb bone,17,18 and is implicated
in the degradation and damage of articular carti-
lage in individuals with RA and osteoarthritis.19–21
Elevated proinflammatory factors such as TNF-α
and interferon gamma can promote MMP-9 ac-
tivity in local inflammatory cells in collagen II
(CII)-induced arthritis.22 However, MMP-9 gene
knockout (KO) mice display a milder form of 
arthritis than in published murine arthritis 
models.23
Anti-CII antibody is known as an autoanti-
body in patients with RA.24 The model of CII-
specific monoclonal antibody-induced arthritis
(CAIA) is commonly used in the screening of 
antirheumatic drugs because it has various simi-
larities to human RA.25 In the CAIA model, anti-
CII antibody plays an important role and induces
arthritis in mice via passive transfer.25 An arthri-
tis model using a mixture of four monoclonal
anti-CII antibodies has also been established.26,27
This arthritis model can be prepared in constant
yields using various strains of mice independent
of major histocompatibility complex haplotypes.27
However, the mechanism of arthritis development
remains unclear thus far.
Murine collagen-induced arthritis (CIA) is a 
T cell-dependent, antibody-mediated autoimmune
disease directly targeting cartilage CII.28 CAIA re-
veals an acute process that bypasses T and B cell
activation, involves immune complex formation
and complement activation, and is neutrophil-
dependent.29,30 However, the fact CAIA is T cell
activation-dependent was recently reported by
Mitamura et al,31 and CD69 does not play a criti-
cal role in neutrophil activation.32 Their results
demonstrated that administration of CTLA-4.Ig
ameliorated the arthritic score and paw thickness
in the later phase, but not in the early phase of
arthritis. There was no significant stimulatory role
for CD69 in the acute inflammatory response
mediated by neutrophils in CAIA.32 In CIA, T and
B cell responses against collagen, joint inflam-
mation, and local synthesis of proinflammatory
mediators are enhanced in CD69−/− mice, and
this increase is associated with decreased produc-
tion of transforming growth factor (TGF)-β.33
The decrease in joint TGF-β levels observed in
CIA was likewise observed in the CAIA model.32
The development of human RA has two stages.
An initial response induced by foreign antigens
(most likely infectious organisms) activates in-
nate immunity accompanied by proinflammatory
cytokine and chemokine secretion, and subse-
quently develops into a self-sustaining T cell-
driven autoimmune process.34 Wang et al revealed
that CAIA, a model of human RA, is a bipartite
disease characterized by an early innate immune
system component intact in RAG2−/− mice and a
later adaptive immune system phase.35 CAIA is
also a TNF-α/IL-1β-dependent inflammatory dis-
ease,36 reflecting the key roles of TNF-α and
IL-1β in the pathogenesis of RA in humans. In
addition, CAIA offers several key advantages over
the classic CIA model. These include rapid dis-
ease onset, high uptake rate, synchronicity, and
the capacity to use genetically modified mice,
such as transgenic and KO mice.37
In this paper, we describe the pathogenesis,
IL-1β protein expression, and relative expression
levels of MMP-9 and IL-1β mRNAs in acute and
chronic stages of the CAIA model.
Methods
Mice
Male BALB/cByJNarl (BALB/c) mice, 6–8 weeks
old, were purchased from the National Laboratory
Animal Center (Taiwan) and subsequently bred
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and maintained under pathogen-free conditions
in the Laboratory Animal Center of the National
Defense Medical Center (Taipei, Taiwan).
Induction of arthritis
An arthritogenic monoclonal antibody (mAb)
cocktail and lipopolysaccharide (LPS) were pur-
chased from Immuno-Biological Laboratories
(Hamburg, Germany) (Chemicon, Germany).
Arthritis was induced by the method of Terato 
et al27 using an arthritogenic mAb cocktail. This
contained four mAbs (F10, A2, D8, and D1) in
equal amounts; three clones (F10, A2, and D8)
were of type IgG2a and one clone (D1) was of
type IgG2b. For the induction of arthritis, each
mouse was injected intravenously with 2 mg of
anti-CII mAb followed by an intraperitoneal 
injection of 50 µg (BALB/c background) LPS
(Escherichia coli 0111:B4) 3 days later.
Clinical symptom evaluation
Arthritis development was monitored in all four
limbs using a macroscopic scoring system. Briefly,
one point was given for each swollen or red toe,
one point for each swollen joint (metatarsal pha-
langeal joints, metacarpal phalangeal joints,
proximal interphalangeal joints, and distal inter-
phalangeal joints), and five points for a swollen
ankle (maximum score: 15 per limb, 60 per
mouse).38 The mice were examined on days 0, 3,
7, and 10 after the mAb injection. The thickness
of each paw was measured in a noncontact man-
ner using a Simplified Geometry Measurement
System (Advanced Design Research Technology
Co. Ltd.). Images of the paws of each mouse
were recorded three times. One trained researcher
who was blinded to group treatments evaluated
the image data independently.
Histology
Ankle joints were fixed in 10% formalin, decalci-
fied, trimmed, and embedded in paraffin wax.
Sections were prepared from the tissue blocks
and stained with hematoxylin and eosin for his-
topathologic scoring. Ankle joints of arthritic
mice were given scores of 0–5 for inflammation,
according to the following criteria: 0, normal; 1,
minimal infiltration of inflammatory cells in the
periarticular area; 2, mild infiltration; 3, moder-
ate infiltration; 4, marked infiltration; and 5, se-
vere infiltration.39 Each slide was scored by three
independent observers and the average score 
was used.
RNA isolation, reverse transcription, and
quantitative polymerase chain reaction
(PCR) amplification 
Total RNA was isolated using the Trizol method,
with homogenization of the footpad tissues in
Trizol lysis buffer followed by chloroform extrac-
tion (Life Technologies). The RNA was eluted
with 20 µL of RNase-free water. All RNA was
quantified by spectrophotometer using the opti-
cal density 260/280 nm ratios. For cDNA syn-
thesis, 5 µg total RNA was reverse transcribed at
50°C for 60 minutes using 200 units Superscript
III reverse transcriptase (Invitrogen, Carlsbad,
CA, USA).
The primer sequences were as follows: MMP-9,
forward primer (5-GGAACTCACACGACATCT-
TCCA-3), reverse primer (5-GAAACTCACACG-
CCAGAAGAATTT-3); IL-1β, forward primer
(5-CCAGCAGGTTATCATCATCATCC-3), reverse
primer (5-CTCGCAGCAGCACATCAAC-3); TNF-
α, forward primer (5-GGGCCACCACGCTCTTC-
TGTCT), reverse primer (5-GCCACTCCAGCTGC-
TCCTCCAC); glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), forward primer (5-TGG-
CAAAGTGGAGATTGTTGCC-3), reverse primer
(5-AAGATGGTGATGGGCTTCCCG-3).
The SYBR Green master mix kit (Bio-Rad,
Hercules, CA, USA) was used for all reactions
with real-time PCR. Briefly, PCR was performed
as follows: 94°C for 2 minutes followed by 40 cy-
cles of denaturation at 94°C for 15 seconds, an-
nealing at 64°C for 30 seconds, extension at 72°C
for 45 seconds, and a final extension at 72°C for
10 minutes. PCR amplifications for each sample
were done in triplicate for all the products and for
the GAPDH controls. Ratios for each product/
GAPDH mRNA were calculated for each sample.
The data were expressed as the fold increases or
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decreases in mRNA level. For all real-time PCR
assays, the products were run on gels to confirm
the presence of a single band.
Cytokine assay
Whole blood was harvested from anesthetized
BALB/c mice and the serum was prepared and 
extracted. Enzyme-linked immunosorbent assay
(ELISA) for IL-1β and TNF-α were performed
using purified mAb-coated plates. All procedures
followed the standard protocols provided by
R&D Systems (Minneapolis, MN, USA). Cytokine
concentrations were measured using an MRX mi-
croplate reader (Dynex Technologies, Chantilly,
VA, USA) at 450 nm (reference, 540 nm).
Statistical analysis
Statistical significance was determined using the
Mann-Whitney nonparametric U test. Values are
shown as mean ± SEM; p < 0.05 was considered
statistically significant.
Results
Clinical presentation of acute stage CAIA
One day following the injection of LPS (4 days
post injection), the mice developed diarrhea,
general weakness, and decreased activity; body
weight decreased and remained low throughout
the course of the experiment until day 10. Start-
ing on day 5, slight signs of swelling were ob-
served and continued to increase until days 7–10,
at which point swelling and redness reached a
peak (Figure 1). Footpad thickness showed a dra-
matic increase from days 7–10 (Figure 1C) com-
pared to baseline; the footpad thickness at day 7
showed an average increase of 0.76±0.07 mm and
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Figure 1. Inflammation produced in a murine CAIA model. The mice were examined on days 0, 3, 7, and 10 after mAb
injection. (A) Photograph of fore and hind paws on day 0. (B) Photograph of obvious swelling and redness of paws on
day 10. (C) Changes in footpad thickness showing dramatic changes on days 7 and 10. The footpad thickness at day 7
showed an average increase of 0.76 ± 0.07 mm and that at day 10 showed an average increase of 0.96 ± 0.09 mm
(n = 20; p < 0.001). (D) Time course change of arthritis score showing dramatic changes on days 7 and 10. The arthritis
score at day 7 was 39.60 ± 3.73 and that at day 10 was 37.96 ± 3.20 (n = 20, p < 0.001).
at day 10 showed an average increase of 0.96 ±
0.09 mm (n = 20; p < 0.001). Arthritis scores also
showed a sudden increase between days 7 and 10
(Figure 1D); the mean score at day 7 was 39.60 ±
3.73 and that of day 10 was 37.96 ± 3.20 (n = 20,
p < 0.001). Thus, pathogenesis developed system-
ically. Histology also showed that inflammation
developed locally in joint areas, as indicated by an
infiltration of immune cells. There were neutro-
phils, macrophages and lymphocytes. The major
type of immune cell was neutrophils (75.52 ±
4.15%), and the percentage of macrophages in the
total inflammatory cells was around 20.55±4.05%.
There were few lymphocytes (3.93 ± 0.36%) in
the inflammatory cells. The inflammatory score
at day 10 reached a mean of 3.96 ± 0.174 (n =
12), indicating a marked inflammatory response
(Figure 2).
Cytokine expression in acute stage CAIA
The mean level of IL-1β in the serum of mice on
day 10 was 37.51 ± 8.56. However, TNF-α was un-
detectable (data not shown, n = 4). The mRNA ex-
pression levels of IL-1β and MMP-9 in the footpads
of the mice on day 10 were 5258.1 ± 1671.2 and
7566 ± 2081 (n = 9), respectively. The mRNA ex-
pression level of TNF-α was much lower than
that of IL-1β during the acute stage (27.53 ± 7.08,
n = 4).
IL-1b and MMP-9 mRNA expression levels in
chronic stage CAIA
The inflammatory score at the chronic stage of
this CAIA model (day 21) was 1.5 ± 0.62 (n = 4;
Figure 3A). There was much less inflammatory
cell infiltration in this chronic stage than during
the acute stage. The mRNA expression levels of
IL-1β and MMP-9 in the footpads of the mice on
day 21 were 17.9 ± 9.5 (n = 4) and 838.9 ± 390.6
(n = 3), respectively (Figure 3B).
Discussion
MMP-9 plays a crucial role in the migration of
macrophages and neutrophils in RA19,40 and
MMP-9 KO mice do not develop severe arthritis
in a murine arthritis model.23 However, there are
no data on MMP-9 mRNA expression levels in
the CAIA model. However, Simard et al41 showed
MMP-9 mRNA as a therapeutic marker in arthritis
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in the CAIA model. (A) Normal ankle joint section 
(hematoxylin & eosin, 200×). (B) Severe synovitis of 
the ankle joint on day 10. (C) The inflammation score 
on day 10 was increased to 3.96 ± 0.174 (n = 12).
that the level of MMP-9 mRNA produced is not
indicative of net proteolytic activity. In our study,
the expression levels of MMP-9 and IL-1β mRNAs
were indicative of clinical disease activity. The
relative expression level of MMP-9 mRNA was
still high during the chronic stage. The IL-1β
mRNA relative expression level was much lower
than MMP-9 in chronic stage CAIA but was also
much lower than IL-1β in acute stage CAIA.
Thus, MMP-9 mRNA appears to be a therapeutic
marker in both acute and chronic stages of the
CAIA model but that of IL-1β is a therapeutic
marker only in the acute stage. MMP-9 is synthe-
sized by a variety of cell types, but due to its ex-
tensive proteolytic ability, normal expression of
MMP-9 is very low and tightly regulated. How-
ever, cytokines such as IL-1β, TNF-α, tumor pro-
moting agent, TGF-β, LPS, oncogenes, and the
agents that stimulate cell migration will induce
pro-MMP-9 in most cells.42–45
This may explain why MMP-9 mRNA expres-
sion was higher than IL-1β mRNA in the acute
stage of CAIA. Chondrocytes and synoviocytes,
the resident cells of the joint capsule, markedly
increase transcription of MMP-9 in response to
IL-1β- and TNF-α-mediated stimulation.46 MMP-9
is also highly expressed in monocytes (osteoclast
precursors) and in multinucleated osteoclasts
that reabsorb bone,17,18 and is implicated in the
degradation and damage of articular cartilage in
individuals with RA and osteoarthritis.19–21 How-
ever, there was little inflammatory cell infiltration
in ankle joints in chronic stage of CAIA, support-
ing MMP-9 mRNA expression as a therapeutic
marker in chronic stages of the CAIA model but
not IL-1β.
Kagari et al revealed that IL-1β and TNF-α
play more crucial roles than IL-6 or chemokines
in CAIA.47 Although the concentration of TNF-α
in hind paws was lower than the lowest detection
limit of ELISA from days 0 to 7, a transient eleva-
tion of the TNF-α level was confirmed from days
3–4. In our study, the serum TNF-α was un-
detectable and the relative expression level of
TNF-α mRNA was mush lower than IL-1β and
MMP-9 in the acute inflammatory stage. These
results are compatible with previous reports.
Although in our CAIA model, all the mice de-
veloped RA, there was occasional partial induc-
tion or uneven footpad swelling. To avoid this, it
is important to take note of several details. First,
special care should be taken when injecting the
antibodies and it is important they are injected
intravenously without leakage. Similar care should
be taken when injecting LPS into the intraperi-
toneal area. Second, the amount of LPS adminis-
tered should be adjusted according to the weight
of each mouse. Third, arthritis can be induced 
in mice at 6–8 weeks of age but younger mice 
are more susceptible to pathogenesis and show 
a more complete induction and more even foot-
pad swelling. This CAIA murine model has the
advantage of rapid induction; it is flexible as it is
applicable to many different strains of mice and
W.T. Chia, et al
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Figure 3. (A) Inflammatory score in chronic stage CAIA. The inflammatory score at the chronic stage of CAIA model (day 21)
was 1.5 ± 0.62 (n = 4). (B) IL-1β and MMP-9 mRNA relative expression level in chronic stage CAIA. The mRNA expression
levels of IL-1β and MMP-9 in the footpads of the mice on day 21 were 17.9 ± 9.5 (n = 4) and 838.9 ± 390.6 (n = 3).
offers a high success rate in terms of induction
and the severity of pathogenesis. Thus, it is ap-
propriate for the therapeutic evaluation of anti-
inflammatory drugs and for testing gene therapy
in the acute and chronic stages of RA.
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